until its acquisition by LEO Pharma A/S in 2009. Wiggans served as Chief Executive Officer and Chairman of the Board of Directors of Peplin, Inc. Wiggans most recently served as Chief Executive Officer and Chairman of the Board of Directors of Dermira, which he co-founded in 2010, until its acquisition by Eli Lilly in 2020 for $1.1 billion. Tom Wiggans has 40 years of experience in the biopharmaceutical industry, including over 25 years of chief executive leadership. I am honored to join the Pardes team and its battle against COVID, and I look forward to working with the executive team and the Pardes board to develop the operational capabilities and strategic relationships to help bring these potential therapies to patients as quickly as possible.”
![pardes biosciences pardes biosciences](https://www.pardesbio.com/wp-content/uploads/2021/12/Pardes_Figures_20211123_Web-1.png)
![pardes biosciences pardes biosciences](https://bookface-images.s3.amazonaws.com/small_logos/7a90b132bd3ef57761690e68c3355e7471e2abf7.png)
I thank the people working to ensure that we have better treatments for current patients and are better prepared for future pandemics. We must continue to accelerate these efforts. Yet vaccines and therapies have been developed in record time, helping us avoid a pandemic that could have been much worse. “The COVID pandemic has had a profound impact on our planet, inflicting terrible human and economic consequences. I commend the Pardes team for their commitment, expertise, and accomplishments,” said Tom Wiggans, Chief Executive Officer and Chair of Pardes Biosciences. “Pardes has made tremendous progress developing PBI-0451 and advancing an exciting anti-viral platform in a very short period of time. As we continue to evolve, Tom’s expertise in growing and leading biotech companies through development and commercialization makes him the perfect successor," said Uri Lopatin, M.D., Founder and former Chief Executive Officer of Pardes Biosciences. Pardes has moved at “warp speed” from a discovery company to a clinical stage company. "It’s my privilege to welcome Tom as Pardes Biosciences’ new Chief Executive Officer and Chairman of its Board of Directors. In addition, Mark Auerbach will transition from Chairman to Board Director. will remain on the Board of Directors and continue to play an active role in the company’s research and development activities as Chief Scientific & Strategic Advisor.
![pardes biosciences pardes biosciences](https://assets.bwbx.io/images/users/iqjWHBFdfxIU/itHOUXSj7kxA/v1/1200x-1.jpg)
Wiggans as Chief Executive Officer and Chair of the Board of Directors. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced the appointment of Thomas G. to transition to Chief Scientific & Strategic Advisor Mark Auerbach to transition from Chairman to Board DirectorĬARLSBAD, Calif., Ma(GLOBE NEWSWIRE) - Pardes Biosciences, Inc. His expertise will be beneficial to Pardes as the company rapidly progresses to late-stage development and regulatory activities, as well as the initial phases of commercialization build-out Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple successful acquisitions.